Your browser is no longer supported. Please, upgrade your browser.
Settings
IONS [NASD]
Ionis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.87 Insider Own0.40% Shs Outstand140.96M Perf Week2.96%
Market Cap4.91B Forward P/E- EPS next Y-1.71 Insider Trans-5.78% Shs Float139.89M Perf Month-3.65%
Income-542.00M PEG- EPS next Q-0.46 Inst Own89.20% Short Float4.75% Perf Quarter-1.29%
Sales687.70M P/S7.14 EPS this Y-257.00% Inst Trans-0.00% Short Ratio7.83 Perf Half Y-12.12%
Book/sh4.13 P/B8.50 EPS next Y3.80% ROA-21.20% Target Price55.82 Perf Year-27.31%
Cash/sh14.73 P/C2.38 EPS next 5Y- ROE-64.00% 52W Range32.15 - 64.37 Perf YTD-37.92%
Dividend- P/FCF- EPS past 5Y-34.40% ROI-29.00% 52W High-45.47% Beta1.05
Dividend %- Quick Ratio7.50 Sales past 5Y20.80% Gross Margin98.30% 52W Low9.18% ATR1.11
Employees757 Current Ratio7.60 Sales Q/Q-13.50% Oper. Margin-33.80% RSI (14)49.95 Volatility3.30% 3.20%
OptionableYes Debt/Eq2.25 EPS Q/Q-211.90% Profit Margin-78.80% Rel Volume2.14 Prev Close34.49
ShortableYes LT Debt/Eq2.13 EarningsAug 04 BMO Payout- Avg Volume848.43K Price35.10
Recom2.60 SMA201.25% SMA50-5.02% SMA200-19.60% Volume1,811,796 Change1.77%
May-07-21Upgrade UBS Sell → Neutral $33 → $37.50
Mar-01-21Upgrade Barclays Underweight → Equal Weight $50 → $52
Dec-16-20Initiated UBS Sell $34
Dec-15-20Upgrade Cowen Market Perform → Outperform
Sep-14-20Resumed JP Morgan Neutral $63
Sep-02-20Initiated The Benchmark Company Hold
Jun-01-20Resumed Oppenheimer Outperform
May-13-20Initiated RBC Capital Mkts Outperform $71
Mar-05-20Initiated Citigroup Buy $73
Dec-13-19Initiated Oppenheimer Outperform
Nov-13-19Initiated BofA/Merrill Buy $70
Nov-07-19Downgrade Morgan Stanley Equal-Weight → Underweight $63 → $48
Sep-10-19Upgrade Bernstein Mkt Perform → Outperform
Aug-08-18Reiterated Stifel Hold $48 → $47
Aug-07-18Reiterated Stifel Hold $55 → $48
May-08-18Downgrade Evercore ISI Outperform → In-line
Oct-06-17Resumed Goldman Sell $30
Aug-17-17Initiated Evercore ISI Outperform $65
Aug-09-17Reiterated Stifel Hold $42 → $50
Mar-10-17Downgrade Goldman Neutral → Sell
Oct-14-21 04:06PM  
Sep-29-21 06:12AM  
Sep-15-21 07:30AM  
Sep-03-21 11:31AM  
07:05AM  
Sep-02-21 07:05AM  
Aug-09-21 04:11AM  
Aug-05-21 10:15AM  
Aug-04-21 06:01PM  
08:25AM  
07:00AM  
Aug-02-21 09:30AM  
Jul-29-21 07:05AM  
Jul-28-21 03:04PM  
Jul-26-21 04:35PM  
Jul-21-21 07:05AM  
Jul-20-21 10:29AM  
Jul-14-21 09:55AM  
Jul-13-21 08:06AM  
06:59AM  
Jul-12-21 05:55AM  
Jul-08-21 09:07AM  
Jul-06-21 06:30AM  
Jun-19-21 06:02AM  
Jun-14-21 04:05PM  
Jun-10-21 06:05PM  
07:30AM  
Jun-04-21 11:31AM  
Jun-02-21 07:59PM  
09:40AM  
May-31-21 06:01AM  
May-26-21 07:05AM  
May-06-21 09:20AM  
07:05AM  
12:30AM  
May-05-21 04:05PM  
11:08AM  
08:25AM  
07:00AM  
Apr-28-21 12:34PM  
Apr-21-21 07:05AM  
Apr-20-21 07:05AM  
Apr-19-21 07:30AM  
Apr-11-21 09:03AM  
Apr-08-21 09:00AM  
07:05AM  
Apr-07-21 07:15AM  
Apr-06-21 04:36PM  
09:44AM  
02:10AM  
Apr-05-21 11:00AM  
07:05AM  
Apr-02-21 10:45PM  
Mar-31-21 11:07PM  
Mar-30-21 03:05AM  
Mar-29-21 07:05AM  
Mar-26-21 11:31AM  
07:05AM  
Mar-25-21 11:51AM  
Mar-24-21 03:43PM  
03:02PM  
Mar-23-21 11:47PM  
06:22PM  
10:38AM  
09:22AM  
08:09AM  
06:54AM  
04:17AM  
04:14AM  
Mar-22-21 05:33PM  
04:01PM  
Mar-08-21 08:05AM  
Mar-01-21 07:05AM  
Feb-24-21 04:00PM  
07:00AM  
Feb-19-21 07:05AM  
Feb-11-21 07:05AM  
Feb-10-21 02:40AM  
Feb-08-21 09:59AM  
Jan-15-21 04:22PM  
04:19PM  
Jan-08-21 07:30AM  
Jan-07-21 05:30PM  
Jan-05-21 07:05AM  
Dec-23-20 02:03AM  
Dec-17-20 06:30PM  
Dec-08-20 09:15PM  
Dec-04-20 11:31AM  
Dec-02-20 07:05AM  
Dec-01-20 05:10PM  
07:05AM  
Nov-30-20 05:15PM  
Nov-23-20 05:15PM  
Nov-13-20 07:05AM  
Nov-12-20 07:05AM  
Nov-10-20 07:05AM  
Nov-09-20 07:05AM  
03:00AM  
Nov-08-20 08:28AM  
Nov-06-20 03:00AM  
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KLEIN JOSEPH IIIDirectorJul 15Option Exercise0.008,666022,460Jul 19 08:14 PM
BERTHELSEN SPENCER RDirectorJul 15Option Exercise0.008,6660109,649Jul 19 08:13 PM
Hayden Michael RDirectorJul 15Option Exercise0.007,111012,445Jul 19 08:13 PM
WENDER JOSEPH HDirectorJul 15Option Exercise0.008,666096,971Jul 19 08:17 PM
PARSHALL B LYNNEDirectorJul 15Option Exercise0.008,000073,378Jul 19 08:16 PM
Reikes Peter NDirectorJul 15Option Exercise0.007,111012,445Jul 19 08:16 PM
LOSCALZO JOSEPHChairman of BoardJul 15Option Exercise0.008,666025,974Jul 19 08:14 PM
MUTO FREDERICK TDirectorJul 15Option Exercise0.008,666040,349Jul 19 08:15 PM
HERMAN JOAN EDirectorJul 15Option Exercise0.007,111016,000Jul 19 08:13 PM
KLEIN JOSEPH IIIDirectorJul 15Sale35.304,334152,98918,126Jul 19 08:14 PM
BERTHELSEN SPENCER RDirectorJun 23Option Exercise9.3015,000139,500115,983Jun 25 05:19 PM
BERTHELSEN SPENCER RDirectorJun 23Sale37.7415,000566,100100,983Jun 25 05:19 PM
MUTO FREDERICK TDirectorJun 15Option Exercise9.3015,000139,50036,683Jun 17 05:05 PM
MUTO FREDERICK TDirectorJun 15Sale36.6315,000549,50031,683Jun 17 05:05 PM
HERMAN JOAN EDirectorJun 10Option Exercise0.003,55508,889Jun 14 06:46 PM
Cadoret-Manier OnaizaChief Corp Dev and Cml OfficerApr 15Option Exercise0.005,66706,159Apr 19 05:04 PM
Monia Brett PChief Executive OfficerMar 01Sale54.2723612,80950,114Mar 02 08:22 PM
CROOKE STANLEY TExec Chairman of the BoardJan 26Sale63.7428,3331,805,8122,021Jan 28 07:22 PM
O'NEIL PATRICK R.EVP & General CounselJan 25Sale63.505,324338,07426,502Jan 27 05:35 PM
CROOKE STANLEY TExec Chairman of the BoardJan 22Sale61.6740,0002,467,000494,391Jan 25 08:24 PM
CROOKE STANLEY TExec Chairman of the BoardJan 21Sale61.2035,0002,142,117534,391Jan 25 08:24 PM
CROOKE STANLEY TExec Chairman of the BoardJan 15Option Exercise0.004,37104,545Jan 20 07:12 PM
CROOKE STANLEY TExec Chairman of the BoardJan 15Option Exercise0.0047,257049,278Jan 20 07:12 PM
BENNETT C FRANKChief Scientific OfficerJan 15Option Exercise0.0015,520047,996Jan 20 07:08 PM
Geary Richard SEVP, Chief Development OffcJan 15Option Exercise0.0017,598047,904Jan 20 07:06 PM
HOUGEN ELIZABETH LEVP, Finance & CFOJan 15Option Exercise0.0017,151049,646Jan 20 07:04 PM
Monia Brett PChief Executive OfficerJan 15Option Exercise0.0034,823063,702Jan 20 07:02 PM
O'NEIL PATRICK R.EVP & General CounselJan 15Option Exercise0.0016,504037,682Jan 20 07:00 PM
PARSHALL B LYNNEDirectorJan 15Option Exercise0.0010,655068,119Jan 20 06:59 PM
Schneider EugeneEVP, Chf Clinical Develop OffcJan 15Option Exercise0.007,50309,621Jan 20 06:55 PM
Swayze EricEVP, ResearchJan 15Option Exercise0.008,944014,051Jan 20 06:53 PM
Geary Richard SEVP, Chief Development OffcJan 13Sale59.501418,39030,306Jan 15 05:55 PM
Swayze EricEVP, ResearchJan 05Sale55.9919510,9185,107Jan 06 09:23 PM
PARSHALL B LYNNEDirectorDec 23Sale60.0010,000600,00057,464Dec 28 05:29 PM
CROOKE STANLEY TExec Chairman of the BoardDec 17Sale50.501,40771,054174Dec 17 07:42 PM
CROOKE STANLEY TExec Chairman of the BoardDec 15Sale49.7739,0001,941,225600,391Dec 17 07:42 PM
CROOKE STANLEY TExec Chairman of the BoardDec 07Sale51.6711,000568,350639,391Dec 09 08:14 PM
BENNETT C FRANKChief Scientific OfficerDec 04Option Exercise39.877,947316,84740,423Dec 08 08:49 PM
Monia Brett PChief Executive OfficerDec 04Option Exercise39.8723,840950,50152,719Dec 08 08:51 PM
BENNETT C FRANKChief Scientific OfficerDec 04Sale51.047,947405,61532,476Dec 08 08:49 PM
Monia Brett PChief Executive OfficerDec 04Sale51.0423,8401,216,79428,879Dec 08 08:51 PM
Monia Brett PChief Executive OfficerDec 02Option Exercise39.8721,160843,64950,039Dec 04 08:49 PM
BENNETT C FRANKChief Scientific OfficerDec 02Option Exercise39.877,053281,20339,529Dec 04 08:53 PM
BENNETT C FRANKChief Scientific OfficerDec 02Sale51.327,053361,96032,476Dec 04 08:53 PM
Monia Brett PChief Executive OfficerDec 02Sale51.3221,1601,085,93128,879Dec 04 08:49 PM
CROOKE STANLEY TExec Chairman of the BoardNov 25Option Exercise39.8712,990517,91115,011Nov 30 06:48 PM
HOUGEN ELIZABETH LEVP, Finance & CFONov 25Option Exercise39.8721,680864,38254,175Nov 30 06:49 PM
PARSHALL B LYNNEDirectorNov 25Option Exercise39.873,590143,13371,054Nov 30 06:44 PM
Geary Richard SEVP, DevelopmentNov 25Option Exercise39.8711,920475,25042,367Nov 30 06:46 PM
PARSHALL B LYNNEDirectorNov 25Sale50.053,590179,68067,464Nov 30 06:44 PM
HOUGEN ELIZABETH LEVP, Finance & CFONov 25Sale50.0521,6801,085,08432,495Nov 30 06:49 PM
CROOKE STANLEY TExec Chairman of the BoardNov 25Sale50.0512,990650,1502,021Nov 30 06:48 PM
Geary Richard SEVP, DevelopmentNov 25Sale50.0511,920596,59630,447Nov 30 06:46 PM
PARSHALL B LYNNEDirectorNov 24Option Exercise39.8771028,30868,174Nov 25 06:56 PM
HOUGEN ELIZABETH LEVP, Finance & CFONov 24Option Exercise39.874,320172,23836,815Nov 25 07:02 PM
Geary Richard SEVP, DevelopmentNov 24Option Exercise39.872,38094,89132,827Nov 25 06:58 PM
CROOKE STANLEY TExec Chairman of the BoardNov 24Option Exercise39.872,590103,2634,611Nov 25 07:04 PM
HOUGEN ELIZABETH LEVP, Finance & CFONov 24Sale50.834,320219,58632,495Nov 25 07:02 PM
CROOKE STANLEY TExec Chairman of the BoardNov 24Sale50.832,590131,6502,021Nov 25 07:04 PM
Geary Richard SEVP, DevelopmentNov 24Sale50.832,380120,97530,447Nov 25 06:58 PM
PARSHALL B LYNNEDirectorNov 24Sale50.8271036,08267,464Nov 25 06:56 PM
PARSHALL B LYNNEDirectorNov 23Option Exercise39.873,200127,58470,664Nov 25 06:56 PM
Geary Richard SEVP, DevelopmentNov 23Option Exercise39.8710,700426,60941,147Nov 25 06:58 PM
HOUGEN ELIZABETH LEVP, Finance & CFONov 23Option Exercise39.8719,000757,53045,620Nov 25 07:02 PM
CROOKE STANLEY TExec Chairman of the BoardNov 23Option Exercise39.8750019,9352,081Nov 25 07:04 PM
CROOKE STANLEY TExec Chairman of the BoardNov 23Option Exercise39.8711,600462,49213,621Nov 25 07:04 PM
CROOKE STANLEY TExec Chairman of the BoardNov 23Sale50.0050025,0001,581Nov 25 07:04 PM
CROOKE STANLEY TExec Chairman of the BoardNov 23Sale50.1111,600581,2762,021Nov 25 07:04 PM
HOUGEN ELIZABETH LEVP, Finance & CFONov 23Sale50.1119,000952,09032,495Nov 25 07:02 PM
Geary Richard SEVP, DevelopmentNov 23Sale50.1110,700536,17730,447Nov 25 06:58 PM
PARSHALL B LYNNEDirectorNov 23Sale50.123,200160,38467,464Nov 25 06:56 PM
BENNETT C FRANKChief Scientific OfficerNov 03Option Exercise39.8715,000598,05047,476Nov 05 08:26 PM
BENNETT C FRANKChief Scientific OfficerNov 03Sale46.7715,000701,60032,476Nov 05 08:26 PM
KLEIN JOSEPH IIIDirectorOct 20Sale46.862,889135,38613,794Oct 22 05:36 PM